LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Leanlab launches edtech certification with focus on accountability to classrooms
A new product certification from Leanlab Education means increased transparency for edtech companies — as well as added credibility for their work within schools. “We want to give teachers and school administrators a quick way to understand if an edtech product reflects the insights of educators, students, and parents — the true end users in education — and…
Actor David Dastmalchian fought his own demons; now the KC native is sending ’80s-inspired monsters to you
Growing up in Kansas City, David Dastmalchian was enamored with his hometown’s most shadowy corners: its fabled haunted houses, the shelves of Clint’s Comics, “Crematia Mortem’s Friday” on local TV, and even his Overland Park neighborhood’s mystical-seeming creeks and forests. Each of these childhood haunts planted a seed for the Hollywood actor’s latest project —…
MoodSpark buys defunct startup’s IP, minds focused on disrupting elderly veterans’ depression
A slew of new patents and tools are now in the hands of a KCK-rooted startup that aims to protect aging military veterans that suffer from loneliness, anxiety and depression. MoodSpark has acquired assets previously held by California-based Dthera Sciences — an early leader of the digital therapeutics space, known for its innovative quality of life…
Built to last, bought with intention: How JE Dunn set supplier diversity as a cornerstone
Editor’s note: The following story was sponsored by KC Rising, a regional initiative to help Kansas City grow faster and more intentionally, as part of a campaign to promote its CEO-to-CEO Challenge on supplier diversity. Approaching supplier diversity for the long haul means defining the work — without limiting it, said Jason Banks, describing how Kansas City-based construction icon JE…